Dr. Janice M. Mehnert on Immunotherapy vs BRAF/MEK Inhibitors in the Adjuvant Setting for Melanoma

June 13, 2019
Janice M. Mehnert, MD

Cancer Network spoke with Janice M. Mehnert, MD, of Rutgers Cancer Institute, about the use of immunotherapy vs BRAF/MEK inhibitors in the adjuvant setting for melanoma.

Cancer Network spoke with Janice M. Mehnert, MD, of Rutgers Cancer Institute, about the use of immunotherapy vs BRAF/MEK inhibitors in the adjuvant setting for melanoma.

Related Content:

ASCO Annual Meeting: MelanomaMelanoma
Chronic IRAEs With Adjuvant Anti–PD-1 Therapy More Common Than Previously Understood for Resected Melanoma
Phase 1/2 trial of Darovasertib With or Without Binimetinib Is Feasible, Safe for Metastatic Uveal Melanoma
Positive Efficacy Data Found With Lifileucel TIL Therapy for Pretreated Advanced Melanoma